SNDX - Company ID 0001395937
The table below shows Syndax Pharmaceuticals Inc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $172.35M | $23.68M | $0.00 | $0.00 | $139.71M | $1.52M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $258.78M | $241.65M | $163.03M | $118.50M | $88.25M | $50.44M |
| SG&A |
Syndax Pharmaceuticals Inc reported annual revenue of $172.35M for fiscal year 2025. That is up 627.8% from $23.68M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.22M (FY 2016) to $172.35M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $179.68M |
| $120.88M |
| $66.92M |
| $33.26M |
| $25.24M |
| $22.50M |
| Operating income | -$273.08M | -$339.67M | -$229.95M | -$151.76M | $26.22M | -$71.42M |
| Income tax | $433.00K | - | - | - | $0.00 | $0.00 |
| Net income | -$285.40M | -$318.80M | -$209.40M | -$149.30M | $24.90M | -$73.16M |
| EPS (diluted) | -$3.29 | -$3.72 | -$2.98 | -$2.46 | $0.46 | -$1.87 |